Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
J Nucl Med. 2010 Jul;51(7):1076-83. doi: 10.2967/jnumed.109.073189. Epub 2010 Jun 16.
Hypoxic tumor cells are resistant to radiotherapy and various chemotherapeutic agents. The pretherapeutic assessment of intratumoral hypoxia may allow selection of patients for intensified treatment regimens. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related protein involved in pH regulation and is upregulated in many tumor types. Radionuclide imaging using a monoclonal antibody against CAIX, such as cG250, may allow noninvasive PET of hypoxia in these tumor types. The aims of this study were to investigate whether (89)Zr-labeled cG250-F(ab')(2) allowed visualization of tumor hypoxia using small-animal PET and whether the tracer showed spatial correlation to the microscopic distribution of CAIX-expressing cells in a human head and neck xenograft tumor model.
Athymic mice with subcutaneous human head and neck carcinoma xenografts (SCCNij3) were imaged with small-animal PET after injection of (89)Zr-cG250-F(ab')(2). PET images were parameterized in terms of standardized uptake values (SUVs). After injection with the nitroimidazole hypoxia marker pimonidazole and the perfusion marker Hoechst 33342, the animals were sacrificed, tumors excised, and CAIX- and pimonidazole-marked hypoxia and blood perfusion were analyzed immunohistochemically. (89)Zr-cG250-F(ab')(2) tumor uptake was analyzed by ex vivo activity counting and by autoradiography of tumor sections.
As early as 4 h after administration, accumulation of (89)Zr-cG250-F(ab')(2) in the tumor had occurred and tumors were clearly visualized by PET, with reduced uptake by 24 h after injection. Pixel-by-pixel analysis showed a significant positive spatial correlation between CAIX expression and (89)Zr-cG250-F(ab')(2) localization (r = 0.57-0.74; P < 0.0001). Also, significant correlations were found between pimonidazole staining intensity and (89)Zr-cG250-F(ab')(2) activity concentration, although less strong (r = 0.46-0.68; P < 0.0001). Tumor maximum SUV correlated significantly with tumor uptake determined ex vivo (r = 0.93; P = 0.0067), as did fractions of CAIX and pimonidazole in tumor sections (r = 0.75; P = 0.03 and r = 0.78; P = 0.02, respectively).
(89)Zr-labeled cG250-F(ab')(2) small-animal PET showed rapid accumulation in a head and neck xenograft tumor model with good correlation to CAIX expression on a microscopic level.
研究使用单克隆抗体 cG250 对抗碳酸酐酶 IX(CAIX)的放射性核素成像(如[89Zr]标记的 cG250-F(ab')(2))是否可以利用小动物 PET 来检测肿瘤缺氧,以及示踪剂是否与人类头颈部异种移植肿瘤模型中 CAIX 表达细胞的微观分布存在空间相关性。
对皮下种植有人头颈部鳞癌细胞系(SCCNij3)的裸鼠进行小动物 PET 扫描,注射[89Zr]标记的 cG250-F(ab')(2)后进行扫描。通过标准化摄取值(SUV)对 PET 图像进行参数化。在注射硝基咪唑类缺氧标志物 pimonidazole 和灌注标志物 Hoechst 33342 后,处死动物,切除肿瘤,通过免疫组化分析 CAIX 和 pimonidazole 标记的缺氧和血液灌注。通过离体放射性计数和肿瘤切片的放射自显影分析[89Zr]标记 cG250-F(ab')(2)的肿瘤摄取。
早在给药后 4 h,[89Zr]标记的 cG250-F(ab')(2)就在肿瘤中聚集,PET 可清晰地显示肿瘤,24 h 后注射后摄取减少。像素对像素分析显示,CAIX 表达与[89Zr]标记的 cG250-F(ab')(2)定位之间存在显著的正空间相关性(r = 0.57-0.74;P < 0.0001)。虽然相关性稍弱,但也发现 pimonidazole 染色强度与[89Zr]标记的 cG250-F(ab')(2)的活性浓度之间存在显著相关性(r = 0.46-0.68;P < 0.0001)。肿瘤最大 SUV 与离体测定的肿瘤摄取量显著相关(r = 0.93;P = 0.0067),肿瘤切片中 CAIX 和 pimonidazole 的分数也与肿瘤摄取量显著相关(r = 0.75;P = 0.03 和 r = 0.78;P = 0.02)。
[89Zr]标记的 cG250-F(ab')(2)小动物 PET 在头颈部异种移植肿瘤模型中迅速积聚,与微观水平上的 CAIX 表达具有良好的相关性。